{"pub": "axios", "url": "https://statnews.com/2019/10/22/investors-are-deeply-skeptical-of-biogens-alzheimers-claims-they-still-think-it-could-win-approval", "downloaded_at": "2019-10-23 10:54:28.616332+00:00", "title": "Investors say Biogen is playing \u2018three-card monte\u2019 with Alzheimer\u2019s claims", "language": "en", "text": "Investors are deeply skeptical of Biogen\u2019s Alzheimer\u2019s claims. They still think it could win approval\n\n\u201cThis is basically a game of corporate three-card monte.\u201d\n\nLikening Biogen (BIIB) to a sidewalk confidence game is how one particularly cynical portfolio manager of a biotech hedge fund responded when I asked for his take on Tuesday\u2019s shocking biotech news: Biogen\u2019s decision to resurrect its experimental Alzheimer\u2019s drug aducanumab \u2014 and pursue regulatory approval \u2014 based on a new and more positive analysis from two large clinical trials previously thought to be negative.", "description": "Despite concerns about the company's claims, many investors say they believe its experimental treatment could win FDA approval.", "authors": ["Adam Feuerstein"], "top_image": "https://www.statnews.com/wp-content/uploads/2019/10/3_card_monte_still-1024x576.jpg", "published_at": "2019-10-22"}